Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Middle East Conflict Impacts Australia and New Zealand Businesses 
(4) - EconoTimes)
STAMFORD, Conn., May 07, 2018 -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that between April 23, 2018 and May 7, 2018, the Compensation Committee of Loxo Oncology’s Board of Directors granted non-qualified stock options to purchase an aggregate of 98,525 shares of its common stock to thirteen new employees. The options were granted as an inducement material to the employees’ acceptance of employment with Loxo Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).
Each option has an exercise price equal to the closing price of Loxo Oncology’s common stock on the day of grant. Each option will vest and become exercisable as to 25% of the shares on the first anniversary of the recipient’s start date, and will vest and become exercisable as to the remaining 2.08333% of the shares in 36 equal monthly installments following the first anniversary, in each case, subject to each such employee’s continued employment with Loxo Oncology on such vesting dates.
About Loxo Oncology
Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com.
Contacts for Loxo Oncology, Inc.
Company:
Lauren Cohen
Director, Corporate Communications
[email protected]
Investors:
Peter Rahmer
Endurance Advisors, LLC
415-515-9763
[email protected]
Media:
Dan Budwick
1AB Media
973-271-6085
[email protected]
